La Jolla Pharmaceutical Company

Gilbert M Iverson

Paul A Barstad

David Matthew Marquis

David S Jones

Edward Jess Victoria

Matthew D Linnik

Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.

Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule

The present invention provides domain 1 &#x3b2;GPI polypeptides, polynucleotides encoding these polypeptides, mimetics of these polypeptides, and methods using domain 1 &#x3b2;GPI polypeptides and mimetics. Domain 1 of &#x3b2;GPI has been shown to bind to anti-cardiolipin (&#x3b2;GPI-dependent antiphospholipid) antibodies, which are associated with several pathologies, such as thrombosis and fetal loss. The domain 1 &#x3b2;GPI polypeptides may be used to detect &#x3b2;GPI-dependent antiphospholipid antibodies in a sample. The invention further provides methods of inducing tolerance using these domain 1 &#x3b2;GPI polypeptides.

Therapeutic and diagnostic domain 1 &#x3b2;2GPI polypeptides and methods of using same

Conjugates of stable nonimmunogenic polymers and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are disclosed. Accordingly, these conjugates are useful for treating antibody-mediated pathologies that are caused by foreign or self immunogens.

Growing community of inventors

Del Mar, CA, United States of America

Gilbert M Iverson